120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
低度炎症：腹泻型肠易激综合征的病理生理机制和药物靶点
Authors Ye B , Fu Z, Zhou X , Wang S, Ouyang L, Chen Z, Deng G
Received 5 November 2025
Accepted for publication 9 January 2026
Published 30 January 2026 Volume 2026:19 578822
DOI https://doi.org/10.2147/JIR.S578822
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Nadia Andrea Andreani
Baibai Ye,1 Ziyu Fu,1 Xin Zhou,1 Shengmei Wang,1 Linqi Ouyang,1 Zhen Chen,1 Guiming Deng1,2
1The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China; 2The Second Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China
Correspondence: Zhen Chen, The First Hospital of Hunan University of Chinese Medicine, Hunan, People’s Republic of China, Email chenzhen@hnucm.edu.cn Guiming Deng, The First Hospital of Hunan University of Chinese Medicine, Hunan, People’s Republic of China, Email dengguiming@hnucm.edu.cn
Abstract: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent functional gastrointestinal disorder. Emerging evidence suggests that chronic low-grade inflammation is a significant pathophysiological mechanism, playing a pivotal role in disrupting intestinal homeostasis and driving disease pathogenesis in a subset of patients. Key contributing factors include intestinal immune dysregulation, gut microbiota imbalance, prior infections, and brain-gut axis dysfunction. Within this complex interplay of physiological and pathological processes, the core mechanisms involve abnormal immune cell activation, release of inflammatory mediators, and engagement of key inflammatory signaling pathways. Although current IBS-D management remains largely symptomatic, with no curative approaches available, the growing insight into low-grade inflammatory mechanisms offers new therapeutic prospects. Targeting intestinal low-grade inflammation is emerging as a highly attractive direction for creating novel treatment strategies. Further research is necessary to identify effective inhibitors of low-grade inflammation in IBS-D and to assess whether treatment aimed at this inflammation can prevent or alleviate the development and progression of the disease.
Keywords: irritable bowel syndrome with diarrhea, low-grade inflammation, intestinal immune imbalance, microbiota dysbiosis, infections, dysfunction of the brain-gut axis
1The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China; 2The Second Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, People’s Republic of China
Correspondence: Zhen Chen, The First Hospital of Hunan University of Chinese Medicine, Hunan, People’s Republic of China, Email chenzhen@hnucm.edu.cn Guiming Deng, The First Hospital of Hunan University of Chinese Medicine, Hunan, People’s Republic of China, Email dengguiming@hnucm.edu.cn
Abstract: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent functional gastrointestinal disorder. Emerging evidence suggests that chronic low-grade inflammation is a significant pathophysiological mechanism, playing a pivotal role in disrupting intestinal homeostasis and driving disease pathogenesis in a subset of patients. Key contributing factors include intestinal immune dysregulation, gut microbiota imbalance, prior infections, and brain-gut axis dysfunction. Within this complex interplay of physiological and pathological processes, the core mechanisms involve abnormal immune cell activation, release of inflammatory mediators, and engagement of key inflammatory signaling pathways. Although current IBS-D management remains largely symptomatic, with no curative approaches available, the growing insight into low-grade inflammatory mechanisms offers new therapeutic prospects. Targeting intestinal low-grade inflammation is emerging as a highly attractive direction for creating novel treatment strategies. Further research is necessary to identify effective inhibitors of low-grade inflammation in IBS-D and to assess whether treatment aimed at this inflammation can prevent or alleviate the development and progression of the disease.
Keywords: irritable bowel syndrome with diarrhea, low-grade inflammation, intestinal immune imbalance, microbiota dysbiosis, infections, dysfunction of the brain-gut axis